Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026

2026-04-21 · Source: The AI Journal · Field: Health & Wellbeing — Pharmaceuticals & Biotechnology, Clinical Care & Medical Practice, Health & Medical Research · Depth: Intermediate, short

Summary

Akeso, Inc. (9926.HK) announced positive Phase II results from its COMPASSION-26 study for cadonilimab, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy as a first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC). Presented at the 2026 AACR Annual Meeting, the data, with a median follow-up exceeding two years as of October 20, 2025, showed robust survival benefits, particularly in patients with locally advanced disease. This subgroup achieved a median PFS of 11.1 months and a median OS over 23 months, with 12-month and 24-month OS rates of 91.7% and 44.1% respectively. The regimen also demonstrated strong tumor control across the overall study population, with an objective response rate (ORR) of 33.9% and a disease control rate (DCR) of 96.4%, and a favorable, manageable safety profile with no new signals.

Key takeaway

For oncologists treating advanced pancreatic ductal adenocarcinoma, the positive Phase II results for cadonilimab in combination with chemotherapy suggest a promising new first-line option. You should consider its robust survival benefits, especially for patients with locally advanced disease, and its favorable safety profile when evaluating treatment strategies. This data supports exploring cadonilimab as a cornerstone therapy in challenging cancer settings.

Key insights

Cadonilimab, a bispecific antibody, shows significant survival and tumor control benefits in advanced pancreatic cancer.

Principles

• Bispecific antibodies can target multiple pathways simultaneously.
• Immunotherapy can benefit "cold" tumors and refractory diseases.

Method

The COMPASSION-26 study evaluated cadonilimab plus chemotherapy as first-line treatment for advanced PDAC, assessing survival benefits, tumor control, and safety profile over a two-year median follow-up.

In practice

• Consider cadonilimab for locally advanced PDAC.
• Evaluate bispecific antibodies for difficult-to-treat cancers.

Topics

• Cadonilimab
• Pancreatic Ductal Adenocarcinoma
• Bispecific Antibody
• PD-1/CTLA-4
• COMPASSION-26 Study

Best for: Research Scientist, Domain Expert, Investor

Related on AIssential

• ATUM’s New Lock-In™ Platform Solves Bispecific Mispairing — ATUM's Lock-In™ platform simplifies bispecific antibody development using an IgG-like architecture for enhanced stability and manufacturability.
• Time-Conditioned and Multi-Time Survival Prediction from 2D PET/CT Projections in Lung Cancer — Temporal modeling significantly enhances PET/CT-based overall survival prediction in NSCLC patients.
• Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile — RZ-001, an RNA editing therapy, shows promising efficacy and safety for hepatocellular carcinoma.
• Enhancing success rates in therapeutic antibody design through generative models — DualGPT-AB is a dual-stage GPT framework optimizing therapeutic antibody design for specificity and developability.
• Efferon secures €2.5M to grow blood purification platform — Efferon's hemoadsorption devices provide a certified solution for sepsis and septic shock, including a first-in-Europe pediatric version.
• Multi-phase hybrid metabolomics framework identifies clinically applicable plasma signatures for early detection of gastric cancer — A multi-phase metabolomics framework identifies a 12-metabolite panel for early gastric cancer detection with high accuracy.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by The AI Journal.